BioCentury | Sep 27, 2012
Distillery Therapeutics

Indication: Hepatic disease

...damage. Next steps could include testing IL-1R antagonists in additional models of alcoholic liver disease. Orthogen AG's...
BioCentury | Aug 11, 2008
Clinical News

Orthokine: Phase III data

...presented in 2005 (see BioCentury, Aug. 15, 2005). Data were published in Osteoarthritis and Cartilage. Orthogen AG...
BioCentury | Feb 12, 2007
Company News

Algynomics, Orthogen deal

...identify genetic markers that predict patient response to treatments for orthopedic and rheumatologic diseases, including Orthogen's...
...the next six months. Financial terms were not disclosed. Algynomics Inc. , Chapel Hill, N.C. Orthogen AG...
BioCentury | Aug 15, 2005
Clinical News

Orthokine: Phase III data

...Osteoarthritis Index (WOMAC) score showed an improvement of >50% with Orthokine vs. 20% with controls. Orthogen AG...
Items per page:
1 - 4 of 4
BioCentury | Sep 27, 2012
Distillery Therapeutics

Indication: Hepatic disease

...damage. Next steps could include testing IL-1R antagonists in additional models of alcoholic liver disease. Orthogen AG's...
BioCentury | Aug 11, 2008
Clinical News

Orthokine: Phase III data

...presented in 2005 (see BioCentury, Aug. 15, 2005). Data were published in Osteoarthritis and Cartilage. Orthogen AG...
BioCentury | Feb 12, 2007
Company News

Algynomics, Orthogen deal

...identify genetic markers that predict patient response to treatments for orthopedic and rheumatologic diseases, including Orthogen's...
...the next six months. Financial terms were not disclosed. Algynomics Inc. , Chapel Hill, N.C. Orthogen AG...
BioCentury | Aug 15, 2005
Clinical News

Orthokine: Phase III data

...Osteoarthritis Index (WOMAC) score showed an improvement of >50% with Orthokine vs. 20% with controls. Orthogen AG...
Items per page:
1 - 4 of 4